MDR Bacterial Infections Our Treatment Option

More documents

Recommendations

Info

SME-1, SME-2, SME-3
605040302010019111020107199920002617103421 22 22134215200120022003ESBL producing E. coli4415NARST dataUrine Blood Sputum492213482418200420052006(28 hospitals, 1998-2008)Ceftazidime%R %R4035302520151050%R2000132001ESBL by screen test16 17 192002200320042120052320062620075125202750302120072008200830sputumurineblood50454035302520151050%R706050403020100200019962020981999200020012426147ESBL by screen test2002Cefotaxime3629 2918920034221142001200220032004482415200420052006200732 33522418200559353020063736633420072008Urine Blood Sputum61413238200840sputumurineblood
Page 1 and 2: MDR Bacterial Infections:Our Treatm
Page 5: IDSA News: 10 New Antibiotics by 20
Page 9 and 10: Definition & Action of KPC, CRKP an
Page 11 and 12: Maria Souli, Irene Galani, Anastasi
Page 13 and 14: Antimicrobial Susceptibility for ND
Page 15 and 16: KPC-p K. pneumoniaeisolate. (USA)Ca
Page 18 and 19: MIC distributions of NDM-1 Enteroba
Page 20 and 21: Drug of Choice for ESBL-producingEn
Page 22 and 23: Antimicrobial Option by Risk Level
Page 24 and 25: In vitro activities of fosfomycin a
Page 26 and 27: 0.5, 1.0, 2.0-gm Human Simulated Pr
Page 28 and 29: FIC Index & InterpretationInterpret
Page 30 and 31: FIC Index of MDR P. aeruginosaStrai
Page 32 and 33: Population PharmacokineticAnalysis
Page 34 and 35: Attenuation of Colistin Bactericida
Page 36 and 37: Pharmacokinetic/Pharmacodynamic Det
Page 38 and 39: Recommended Definite Therapy for Se
Page 40 and 41: Breakpoint Criteria of Vancomycin f
Page 42 and 43: One Gram bid: Enough for Vancomycin
Page 44 and 45: การใชยา vancomycin
Page 46 and 47: ยาขนานอื่น ถ
Page 48 and 49: Early Combination Rx vs. Monotherap
Page 54: Thank youAny Comment?Any Question?

MDR Bacterial Infections Our Treatment Option

Create successful ePaper yourself

Delete template?

Save as template?